We are live on ! Find out more
FOCL

EDAP TMS S.A.

4.17 USD
-0.05
1.18%
At close Updated Sep 3, 4:00 PM EDT
1 day
-1.18%
5 days
-5.01%
1 month
-30.15%
3 months
-8.95%
6 months
4.51%
Year to date
22.65%
1 year
51.64%
5 years
-34.23%
10 years
40.88%
 

About: Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.

Employees: 289

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 18.2%
Neutral 81.8%
Negative 0%
Neutral
GlobeNewsWire
2 days ago
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
FocalTherics ™ to Present at the H.C. Wain w right 28 th Annual Global Investment Conference Company to Present and Host 1x1 Investor Meetings on T uesday and Wednesday, September 15 th -16 th , 2026 AUSTIN, Texas, Sept.
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Neutral
Seeking Alpha
21 days ago
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
21 days ago
FocalTherics Q2 Earnings Call Highlights
FocalTherics NASDAQ: FOCL reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy.
FocalTherics Q2 Earnings Call Highlights
Neutral
GlobeNewsWire
21 days ago
FocalTherics™ Reports Second Quarter 2026 Financial Results
FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.
FocalTherics™ Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
23 days ago
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced the pricing of its underwritten public offering of 8,425,000 of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share at a public offering price of $4.75 per ADS, before underwriting discounts and commissions (the “Offering”). All of the ADSs are being sold by the Company.
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
Neutral
GlobeNewsWire
23 days ago
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Company's HIFU segment, reported as continuing operations, for the second quarter of 2026.  During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company's operations and financial results.
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026
Neutral
GlobeNewsWire
23 days ago
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share (the “Offering”). All of the ADSs in the proposed Offering will be sold by the Company.
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares
Positive
Zacks Investment Research
29 days ago
FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains?
FocalTherics (FOCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains?
Neutral
GlobeNewsWire
1 month ago
FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT
FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
Neutral
GlobeNewsWire
2 months ago
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
Price charts implemented using Lightweight Charts™